Unveiling the Functional Roles of Patient-derived Tumour Organoids in Assessing the Tumour Microenvironment and Immunotherapy

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2024 Sep 9

PMID 39245957

Authors

Di Chen

Lixia Xu

Mengjuan Xuan

Qingfei Chu

Chen Xue

Affiliations

Soon will be listed here.

Abstract

Recent studies have established the pivotal roles of patient-derived tumour organoids (PDTOs), innovative three-dimensional (3D) culture systems, in various biological and medical applications. PDTOs, as promising tools, have been established and extensively used for drug screening, prediction of immune response and assessment of immunotherapeutic effectiveness in various cancer types, including glioma, ovarian cancer and so on. The overarching goal is to facilitate the translation of new therapeutic modalities to guide personalised immunotherapy. Notably, there has been a recent surge of interest in the co-culture of PDTOs with immune cells to investigate the dynamic interactions between tumour cells and immune microenvironment. A comprehensive and in-depth investigation is necessary to enhance our understanding of PDTOs as promising testing platforms for cancer immunotherapy. This review mainly focuses on the latest updates on the applications and challenges of PDTO-based methods in anti-cancer immune responses. We strive to provide a comprehensive understanding of the potential and prospects of PDTO-based technologies as next-generation strategies for advancing immunotherapy approaches.

Citing Articles

Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy.

Palacios P, Flores I, Cereceda L, Otero F, Muller M, Brebi P Cancers (Basel). 2025; 17(3).

PMID: 39941775 PMC: 11815936. DOI: 10.3390/cancers17030406.

Tumor organoids in cancer medicine: from model systems to natural compound screening.

Cong R, Lu C, Li X, Xu Z, Wang Y, Sun S Pharm Biol. 2025; 63(1):89-109.

PMID: 39893515 PMC: 11789228. DOI: 10.1080/13880209.2025.2458149.

Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy.

Chen D, Xu L, Xuan M, Chu Q, Xue C Clin Transl Med. 2024; 14(9):e1802.

PMID: 39245957 PMC: 11381553. DOI: 10.1002/ctm2.1802.

References

Connal S, Cameron J, Sala A, Brennan P, Palmer D, Palmer J . Liquid biopsies: the future of cancer early detection. J Transl Med. 2023; 21(1):118. PMC: 9922467. DOI: 10.1186/s12967-023-03960-8. View

Tuysuz N, van Bloois L, van den Brink S, Begthel H, Verstegen M, Cruz L . Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells. Nat Commun. 2017; 8:14578. PMC: 5343445. DOI: 10.1038/ncomms14578. View

Ding S, Hsu C, Wang Z, Natesh N, Millen R, Negrete M . Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell. 2022; 29(6):905-917.e6. PMC: 9177814. DOI: 10.1016/j.stem.2022.04.006. View

Klein E, Hau A, Oudin A, Golebiewska A, Niclou S . Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy. Front Oncol. 2020; 10:604121. PMC: 7753120. DOI: 10.3389/fonc.2020.604121. View

Hu L, Yang X, Lan H, Fang X, Chen X, Jin K . Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold. Exp Cell Res. 2021; 408(2):112858. DOI: 10.1016/j.yexcr.2021.112858. View

Aboulkheyr Es H, Zhand S, Thiery J, Warkiani M . Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integr Biol (Camb). 2020; 12(7):188-197. DOI: 10.1093/intbio/zyaa014. View

Shankara Narayanan J, Hayashi T, Erdem S, McArdle S, Tiriac H, Ray P . Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. J Immunother Cancer. 2023; 11(1). PMC: 9843215. DOI: 10.1136/jitc-2022-006133. View

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber L, Woolston A . CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019; 7(1):101. PMC: 6463631. DOI: 10.1186/s40425-019-0575-3. View

DAngelo A, Shibata K, Tokunaga M, Furutani-Seiki M, Bagby S . Generation of murine tumour-reactive T cells by co-culturing murine pancreatic cancer organoids and peripheral blood lymphocytes. Biochem Biophys Rep. 2022; 32:101365. PMC: 9552097. DOI: 10.1016/j.bbrep.2022.101365. View

10.

Allen J, Rosendahl Huber A, Pleguezuelos-Manzano C, Puschhof J, Wu S, Wu X . Colon Tumors in Enterotoxigenic Bacteroides fragilis (ETBF)-Colonized Mice Do Not Display a Unique Mutational Signature but Instead Possess Host-Dependent Alterations in the APC Gene. Microbiol Spectr. 2022; 10(3):e0105522. PMC: 9241831. DOI: 10.1128/spectrum.01055-22. View

11.

Tan R, Zhang Z, Ding P, Liu Y, Liu H, Lu M . A growth factor-reduced culture system for colorectal cancer organoids. Cancer Lett. 2024; 588:216737. DOI: 10.1016/j.canlet.2024.216737. View

12.

Yuan B, Zhao X, Wang X, Liu E, Liu C, Zong Y . Patient-derived organoids for personalized gallbladder cancer modelling and drug screening. Clin Transl Med. 2022; 12(1):e678. PMC: 8786696. DOI: 10.1002/ctm2.678. View

13.

Ao Z, Wu Z, Cai H, Hu L, Li X, Kaurich C . Rapid Profiling of Tumor-Immune Interaction Using Acoustically Assembled Patient-Derived Cell Clusters. Adv Sci (Weinh). 2022; 9(22):e2201478. PMC: 9353481. DOI: 10.1002/advs.202201478. View

14.

Geyer M, Queiroz K . Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening. Front Cell Dev Biol. 2022; 9:761807. PMC: 8733732. DOI: 10.3389/fcell.2021.761807. View

15.

Koh V, Chakrabarti J, Torvund M, Steele N, Hawkins J, Ito Y . Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021; 518:59-71. PMC: 8606306. DOI: 10.1016/j.canlet.2021.06.007. View

16.

Liu L, Yu L, Li Z, Li W, Huang W . Patient-derived organoid (PDO) platforms to facilitate clinical decision making. J Transl Med. 2021; 19(1):40. PMC: 7821720. DOI: 10.1186/s12967-020-02677-2. View

17.

Bonaventura P, Alcazer V, Mutez V, Tonon L, Martin J, Chuvin N . Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci Adv. 2022; 8(4):eabj3671. PMC: 8791462. DOI: 10.1126/sciadv.abj3671. View

18.

Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y . Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest. 2021; 131(10). PMC: 8121519. DOI: 10.1172/JCI146832. View

19.

Gupta A, Atanasov A, Li Y, Kumar N, Bishayee A . Chlorogenic acid for cancer prevention and therapy: Current status on efficacy and mechanisms of action. Pharmacol Res. 2022; 186:106505. DOI: 10.1016/j.phrs.2022.106505. View

20.

Sun Y, Revach O, Anderson S, Kessler E, Wolfe C, Jenney A . Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023; 615(7950):158-167. PMC: 10171827. DOI: 10.1038/s41586-023-05704-6. View